HCRN-BRE20-442
Phase II Study of The Combination of Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
Learn more:
- clinicaltrials.gov: #NCT05255666
Phase II Study of The Combination of Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
Learn more:
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter